Novartis - CHF Company profile
Novartis AG (NVS) is a global pharmaceutical company. Founded in 1996 through a merger of Ciba-Geigy and Sandoz, Novartis is headquartered in Basel, Switzerland. The firm has two divisions: Innovative Medicines and Sandoz.
Innovative Medicines offer prescription medicines and create treatments in areas of respiratory, ophthalmology, neuroscience, immunology, hepatology, dermatology, cardiovascular, renal and metabolism.
Sandoz develops, manufactures and markets generic pharmaceuticals and biosimilars. Sandoz products include: Adakveo (crizanlizumab), Afinitor Disperz/Votubia (everolimus) and Arzerra (ofatumumab) for Oncology; and Aimovig (erenumab) for neuroscience.
In 2020, in response to the pandemic, the company collaborated with Molecular Partners to develop ensovibep, a DARPin therapeutic candidate designed for potential use against Covid-19.
The company’s shares have been listed on the New York Stock Exchange (NYSE) since 2000. Novartis AG stock is traded under the ticker symbol NVS. You can track live NVS share value and price history at Capital.com.